Clinical significance of MTAP, CDKN2A and CDKN2B expression in diffuse large B-cell lymphoma

( views:254, downloads:0 )
Author:
LI Li()
XU Peng-peng(State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China)
SHEN Zhi-xiang(State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China)
ZHAO Wei-li(State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China)
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 20, Issue 08, 2011
DOI:
10.3760/cma.j.issn.1009-9921.2011.08.006
Key Word:
Lymphoma, large cell, diffuse;Gene expression;Real-time polymerase chain reaction

Abstract: Objective To investigate the clinical significance of MTAP, CDKN2A and CDKN2B gene expression in diffuse large B-cell lymphoma (DLBCL). Methods MTAP, CDKN2A and CDKN2B gene expression were assessed by Real-time quantitative PCR in 40 cases of DLBCL and 19 cases of reactive hyperplasia. The clinical and follow-up data were also collected. Results Comparing with reactive hyperplasia, MTAP, CDKN2A and CDKN2B gene expression were decreased in DLBCL group (P = 0.024,0.044 and 0.047, respectively). Low-expression of all the three genes were associated with advanced Ann Arbor stage (P=0.004, 0.001 and 0.027, respectively). No obvious difference were observed according to gender, age, the number of the extra-nodal infiltration, ECOG score, bone marrow involvement and serum LDH level (P >0.05). MTAP and CDKN2A gene expression were associated with B symptoms (P =0.003 and 0.028, respectively) and IPI scores (P =0.001 and 0.011, respectively). With regard to survival rates,MTAP, CDKN2A and CDKN2B gene expression were significantly associated with OS (P =0.022, 0.019 and 0.042, respectively). Conclusion MTAP, CDKN2A and CDKN2B gene expression in DLBCL were decreased and related to disease progression and prognosis. They could be considered as biomarkers to evaluate biological behavior and clinical outcome of DLBCL patients.

  • [1]Deneberg S,Grovdal M,Karimi M,et al.Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.Leukemia,2010,24:932-941.
  • [2]Kadariya Y,Yin B,Tang B,et al.Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma.Cancer Res,2009,69:5961-5969.
  • [3]Behrmann I,Wallner S,Komyod W,et al.Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.Am J Pathol,2003,163:683-690.
  • [4]Bertin R,Acquaviva C,Mirebeau D,et al.CDKN2A,CDKN2B and MTAP gene dosage permits precise characterization of mono-and biallelic 9p21 deletions in childhood acute lymphoblastic leukemia.Genes Chromosomes Cancer,2003,37:44-57.
  • [5]窦红菊,胡钧培,唐勇,等.弥漫大B细胞淋巴瘤SOCS-1基因异常甲基化的研究.白血病·淋巴瘤,2010,19:678-681.
  • [6]Livak K J,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T))Method.Methods,2001,25:402-408.
  • [7]刘辉,常乃柏,魏健平,等.利妥昔单抗联合化疗治疗弥漫大B细胞淋巴瘤临床分析.白血病·淋巴瘤,2009,18:152-154.
  • [8]Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med,2002,346:235-242.
  • [9]Abramson JS,Shipp MA.Advances in the biology and therapy of diffuse large B-cell lymphoma:moving toward a molecularly targeted approach.Blood,2005,106:1164-1174.
  • [10]Lossos IS,Morgensztern D.Prognostic biomarkers in diffuse large B-cell lymphoma.J Clin Oncol,2006,24:995-1007.
  • [11]Rosenwald A,Wright G,Chan WC,et al.The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.N Engl J Med,2002,346:1937-1947.
  • [12]Kadariya Y,Yin B,Tang B,et al.Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma.Cancer Res,2009,69:5961-5969.
  • [13]Schmid M,Malicki D,Nobori T,et al.Homozygous deletions ofmsthylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2A)homozygous deletions in primary nonsmall cell lung cancers (NSCLC).Oncogene,1998,17:2669-2675.
  • [14]Negríní S,Gorgoulís VG,Halazonetís TD.Genomíc ínstabílíty-an evolving hallmark of cancer.Nat Rev Mol Cell Biol,2010,11:220-228.
  • [15]Senff NJ,Zoutman WH,Vermeer MH,et al.Fine-mapping chromosomal loss at 9p21:correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma,leg type.J Invest Dermatol,2009,129:1149-1155.
  • [16]Jardin F,Jais JP,Molina TJ,et al.Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment:a GELA study.Blood,2010.
  • [17]Deneberg S,Grovdal M,Karimi M,et al.Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.Leukemia,2010,24:932-941.
  • [18]Davidsson J,Paulsson K,Lindgren D,et al.Relapsed childhood high hyperdiploid acute lymphoblastic leukemia:presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTKRAS mutations.Leukemia,2010,24:924-931.
  • [19]Nacheva EP,Brazma D,Virgili A,et al.Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia.BMC Genomics,2010,11:41.
  • [20]Schwindt H,Vater I,Kreuz M,et al.Chromosomal imbalances and partíal uniparental dísordíes ín prímary central nervous system lymphoma.Leukemia,2009,23:1875-1884.
  • [21]Salgado R,Servitje O,Gallardo F,et al.Oligonucleotide array-CGH ídentífíes genomíic subgroups and prognostíc markers for tumor stage mycosis fungoides.J Invest Dermatol,2010,130:1126-1135.
  • [22]Schwaenen C,Viardot A,Berger H,et al.Microarray-based genomic profiling reveals novel genomíc aberratíons ín follícular lymphoma which associate with patient survival and gene expression status.Genes Chromosomes Cancer,2009,48:39-54.
  • [23]Bertino JR,Waud WR,Parker WB,et al.Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity:current strategies.Cancer Biol Ther,2011,11:.
  • [24]Santos FP,Kantarjian H,Garcia-Manero G,et al.Decítabíne ín the treatment of myelodysplastic syndromes.Expert Rev Anticancer Ther,2010,10:9-22.
  • [25]刘艳艳,赵维莅,李玉富等.组蛋白去乙酰化酶抑制剂对B细胞淋巴瘤的体外作用机制.白血病·淋巴瘤,2007,16:416-418.
  • [26]Amara K,Trimeche M,Ziadi S,et al.Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas.Ann Oncol,2008,19:1774-1786.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn